Saniona AB has selected its proprietary GABA-A α5 negative allosteric modulator lead compound, SAN-2465, as a clinical candidate for major depressive disorder following encouraging results in a rodent model.

Enveric Biosciences Inc. has named EB-003 as its lead drug candidate from the company’s next-generation EVM301 series. EB-003 was selected based on data analyses suggesting the molecule’s potential to be a first-in-class approach to addressing difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations.

Novel non-addicting analgetic therapies are urgently needed to reduce the use of opiates as painkillers. With the recent discovery that nicotinic acetylcholine receptors (nAChRs) in the immune system can be stimulated to decrease the release of pro-inflammatory cytokines, the cholinergic anti-inflammatory systems (CAS) have generated significant interest in treating pain associated with inflammation.

Saniona AB has reported that it has selected SAN-2355 as the first clinical candidate from its Kv7 epilepsy program and is poised to advance it into preclinical development.

Frontotemporal lobar degeneration (FTLD) leads to frontotemporal dementia (FTD), a prevalent type of dementia second only to Alzheimer's disease.

Axxam SpA has signed a partnership agreement with Lundbeck A/S aimed at supporting Lundbeck on early-stage drug discovery programs related to CNS indications.

Researchers from Cybin Inc. presented preclinical data for the potent and selective long-acting serotonin 5-HT2A receptor agonist, CYB-210010, as potential therapeutic candidate for the treatment of neurological disorders.